Printer Friendly

U.S. Patent Office Grants Entropin Patent.

Entropin, Inc. (BULLETIN BOARD: ETOP) , a development stage pharmaceutical company focused on the pain therapy market, announced today that its patent, U.S. 6,790,857, entitled, "Novel Benzoylecgonine Compositions and Methods for Producing Them," has been allowed by the United States Patent and Trademark Office. The patent claims define a method for the manufacture of a family of chemical structures built around the chemical building blocks, benzoylecgonine, ecgonine and ecgonidine.

"This patent is important because it covers the manufacturing method we use to produce the active ingredient in our product and expands our patent portfolio. We have also filed composition-of-matter and formulation patents on ENT-103 which, if issued, could extend our patent protection for ENT-103 to 2020," commented Thomas G. Tachovsky, Ph.D., Entropin's president and CEO.

About Entropin

Entropin, Inc. is a pharmaceutical research and development company focused on the development of its proprietary compound, ENT-103, as a potent therapy for pain. Preclinical work shows that ENT-103 effectively blocks nerve impulse conduction, has potentially long-lasting properties to reduce and manage pain and may also be effective in relieving both primary and secondary hyperalgesia (pain hypersensitivity) caused either by injury or incision.

Statements in this press release that are not strictly historical may be "forward-looking" statements, which involve risks and uncertainties. No assurances can be given, for example, that the Company will successfully raise additional capital, develop its current products, or any new products it may pursue, complete preclinical testing and clinical trials, obtain regulatory approvals, obtain patents or be able to protect its intellectual property or be able to manufacture or successfully commercialize such products. Actual results may differ materially from those described in this release due to risks and uncertainties that exist in the Company's operations, including, without limitation, the ability to obtain substantial additional funding, the ability to successfully complete development and commercialization of products, including the cost, scope and results of preclinical and clinical testing, the ability to successfully complete product research and further development, including preclinical and clinical studies, the time, cost and uncertainty of obtaining regulatory approvals, the ability to develop and commercialize products before competitors and other factors detailed from time to time in filings with the Securities and Exchange Commission including, without limitation, the Company's Annual Report on Form 10-KSB for the most recent fiscal year end and the Company's most recent Form 10-QSB. The Company undertakes no obligation to release publicly the results of any revision to these forward-looking statements to reflect events or circumstances arising after the date hereof.

For further information, please contact: Thomas Tachovsky, Ph.D., President and CEO, or Patricia Kriss, CFO and VP, Finance & Administration, both of Entropin, Inc., +1-760-775-8333, info@Entropin.com.

CONTACT: Thomas Tachovsky, Ph.D., President and CEO, or Patricia Kriss, CFO and VP, Finance & Administration, both of Entropin, Inc., +1-760-775-8333, info@Entropin.com

Web site: http://www.entropin.com/
COPYRIGHT 2004 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 19, 2004
Words:478
Previous Article:Level 3 HomeTone(SM) VoIP Solution Enables Broadband Provider Speakeasy to Offer Residential Phone Service in U.S.
Next Article:Neurocrine Submits New Drug Application (NDA) for Indiplon Immediate Release Capsules for the Treatment of Insomnia.


Related Articles
Entropin, Inc. Announces Letter of Intent to Provide CRO Services for Phase IIIA Testing of Esterom.
Thomas G. Tachovsky, Ph.D. Appointed President & Chief Executive Officer Of Entropin, Inc.
Entropin, Inc. Starts Phase III Clinical Trials of its Esterom Solution For the Treatment of Impaired Shoulder Function.
Entropin Provides Business Update; Investor Conference Call to be Held Today at 4:30 p.m. Eastern Time.
Entropin Reports Year-End 2001 Financial Results And Esterom(R) Clinical Progress.
Entropin Announces Research Collaboration Regarding Topical ENT-103.
Entropin Announces Allowance of U.S. Patent for Covalent Compounds Defining a New Platform Technology.
Entropin, Inc. Implements Nationwide Public Relations Program.
Entropin Files Patent for ENT-103, Focuses Development On This Simplified Next Generation Form of ENT-102.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters